RecruitingPhase 2NCT07214987

PDT For Induction Therapy For Head And Neck Cancer

A Phase 2 Study of Toripalimab in Combination With Cisplatin and Docetaxel (PDT) for Induction Therapy in CPS-Positive Locally Advanced Head and Neck Squamous Cell Carcinoma

Sponsor

Massachusetts General Hospital

Enrollment

26 participants

Start Date

Mar 9, 2026

Study Type

INTERVENTIONAL

Conditions

Head and Neck Cancer Squamous Cell Carcinoma Head and Neck Cancer Squamous Cell Carcinoma

Summary

This research study is being done to assess the safety and tolerability of toripalimab in combination with cisplatin and docetaxel (PDT) induction therapy for patients with CPS-positive locally advanced head and neck squamous cell carcinoma (HNSCC).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Cisplatin, a drug called Docetaxel, and others for people with head and neck cancer, head and neck cancer squamous cell carcinoma, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGToripalimab-tpzi

Toripalimab-tpzi is a humanized IgG4 monoclonal antibody specific against human PD-1.

DRUGCisplatin

Cisplatin is an injectable chemotherapy agent classified as a platinum-based alkylating agent.

DRUGDocetaxel

Docetaxel is a taxane chemotherapy agent.

Locations(2)

Massachusetts General Hospital

Boston, Massachusetts, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07214987

Related Trials

To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.

NCT069702754 locations

SGRT in Head and Neck Cancer Radiotherapy

NCT077264071 location

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

NCT0709049930 locations

DESTINY-PANTUMOUR04

NCT0712400018 locations

Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)

NCT071014321 location